# Eyegate Pharmaceuticals, Inc. (EYEG)

Source: https://www.quantisnow.com/company/EYEG
Generated: 2026-11-16T02:42:45.653Z

- Ticker: EYEG
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Major Pharmaceuticals
- IPO year: n/a
- Website: eyegatepharma.com

## About

EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

## Latest EYEG news and filings

- 2023-12-13 12:30 UTC [AllianceBernstein Launches Five New Active ETFs](https://www.quantisnow.com/insight/alliancebernstein-launches-five-new-active-etfs-5134498)
- 2021-11-15 12:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eyegate-pharmaceuticals-inc-2006261)
- 2021-11-10 21:17 UTC [SEC Form 4] [SEC Form 4 filed by Daniels Eric Joseph](https://www.quantisnow.com/insight/sec-form-4-filed-by-daniels-eric-joseph-1991948)
- 2021-11-10 21:15 UTC [SEC Form 3] [SEC Form 3 filed by new insider Daniels Eric Joseph](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-daniels-eric-joseph-1991898)
- 2021-11-08 12:32 UTC [SEC Form 8-K] [Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyegate-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-1972744)
- 2021-11-08 12:30 UTC [EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy](https://www.quantisnow.com/insight/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-1972691)
- 2021-11-04 20:20 UTC [SEC Form D] [SEC Form D filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-eyegate-pharmaceuticals-inc-1963923)
- 2021-11-03 20:16 UTC [SEC Form 4] [SEC Form 4: From Stephen covered exercise/tax liability with 250 shares, decreasing direct ownership by 0.36% to 68,292 units](https://www.quantisnow.com/insight/sec-form-4-from-stephen-covered-exercisetax-liability-with-250-1955467)
- 2021-11-03 20:16 UTC [SEC Form 4] [SEC Form 4: Mann Brenda covered exercise/tax liability with 62 shares, decreasing direct ownership by 0.41% to 15,136 units](https://www.quantisnow.com/insight/sec-form-4-mann-brenda-covered-exercisetax-liability-with-62-1955453)
- 2021-11-03 20:15 UTC [SEC Form 4] [SEC Form 4: Romano Sarah covered exercise/tax liability with 83 shares, decreasing direct ownership by 0.36% to 23,059 units](https://www.quantisnow.com/insight/sec-form-4-romano-sarah-covered-exercisetax-liability-with-83-1955445)
- 2021-10-26 11:00 UTC [SEC Form 8-K] [Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyegate-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-1912457)
- 2021-10-26 11:00 UTC [Leadership Update] [EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.](https://www.quantisnow.com/insight/eyegate-pharmaceuticals-appoints-eric-j-daniels-md-mba-as-chief-1912438)
- 2021-10-05 22:40 UTC [SEC Form 4] [SEC Form 4: Romano Sarah covered exercise/tax liability with 83 shares, decreasing direct ownership by 0.36% to 23,142 units](https://www.quantisnow.com/insight/sec-form-4-romano-sarah-covered-exercisetax-liability-with-83-1845547)
- 2021-10-05 22:40 UTC [SEC Form 4] [SEC Form 4: Mann Brenda covered exercise/tax liability with 62 shares, decreasing direct ownership by 0.41% to 15,198 units](https://www.quantisnow.com/insight/sec-form-4-mann-brenda-covered-exercisetax-liability-with-62-1845546)
- 2021-10-05 22:39 UTC [SEC Form 4] [SEC Form 4: From Stephen covered exercise/tax liability with 249 shares, decreasing direct ownership by 0.36% to 68,542 units](https://www.quantisnow.com/insight/sec-form-4-from-stephen-covered-exercisetax-liability-with-249-1845545)
- 2021-09-14 20:20 UTC [SEC Form 8-K] [Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyegate-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-1771468)
- 2021-09-09 20:15 UTC [Conference Announcement] [EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference](https://www.quantisnow.com/insight/eyegate-to-present-at-the-hc-wainwright-23rd-annual-global-1757341)
- 2021-09-08 10:55 UTC [EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation](https://www.quantisnow.com/insight/eyegate-pharma-completes-target-enrollment-in-phase-2-proof-of-concept-study-1748322)
- 2021-09-03 20:17 UTC [SEC Form 4] [SEC Form 4: From Stephen covered exercise/tax liability with 253 units of Common Stock, decreasing direct ownership by 0.37% to 68,791 units](https://www.quantisnow.com/insight/sec-form-4-from-stephen-covered-exercisetax-liability-with-253-1740853)
- 2021-09-03 20:16 UTC [SEC Form 4] [SEC Form 4: Romano Sarah covered exercise/tax liability with 84 units of Common Stock, decreasing direct ownership by 0.36% to 23,225 units](https://www.quantisnow.com/insight/sec-form-4-romano-sarah-covered-exercisetax-liability-with-84-1740815)
- 2021-09-03 20:15 UTC [SEC Form 4] [SEC Form 4: Mann Brenda covered exercise/tax liability with 61 units of Common Stock, decreasing direct ownership by 0.40% to 15,260 units](https://www.quantisnow.com/insight/sec-form-4-mann-brenda-covered-exercisetax-liability-with-61-1740813)
- 2021-08-26 20:16 UTC [SEC Form 8-K] [Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/eyegate-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-1713295)
- 2021-08-23 20:15 UTC [SEC Form D] [SEC Form D filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-eyegate-pharmaceuticals-inc-1698758)
- 2021-08-20 20:45 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eyegate-pharmaceuticals-inc-1694373)
- 2021-08-20 20:40 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eyegate-pharmaceuticals-inc-1694334)
- 2021-08-19 20:30 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eyegate-pharmaceuticals-inc-1690682)
- 2021-08-18 20:17 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eyegate-pharmaceuticals-inc-1685335)
- 2021-08-17 20:45 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eyegate-pharmaceuticals-inc-1680652)
- 2021-08-16 14:16 UTC [Analyst Coverage Reiterated] [HC Wainwright & Co. reiterated coverage on Eyegate Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/hc-wainwright-co-reiterated-coverage-on-eyegate-pharmaceuticals-with-a-1672353)
- 2021-08-13 20:01 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-eyegate-pharmaceuticals-inc-1668355)
- 2021-08-12 20:19 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eyegate-pharmaceuticals-inc-1664055)
- 2021-08-12 20:15 UTC [Public Offering] [EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/eyegate-pharma-reports-second-quarter-2021-financial-results-and-provides-1663809)
- 2021-08-11 20:15 UTC [Public Offering] [EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules](https://www.quantisnow.com/insight/eyegate-announces-closing-of-1075-million-registered-direct-offering-priced-1657576)
- 2021-08-11 10:56 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Eyegate Pharmaceuticals, Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-eyegate-pharmaceuticals-inc-1653741)
- 2021-08-10 10:55 UTC [SEC Form 8-K] [Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyegate-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-1647326)
- 2021-08-10 10:55 UTC [Public Offering] [EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules](https://www.quantisnow.com/insight/eyegate-announces-1075-million-registered-direct-offering-priced-at-the-market-under-1647314)
- 2021-08-04 21:45 UTC [SEC Form 4] [SEC Form 4: Romano Sarah covered exercise/tax liability with 87 units of Common Stock, decreasing direct ownership by 0.37% to 23,309 units](https://www.quantisnow.com/insight/sec-form-4-romano-sarah-covered-exercisetax-liability-with-87-1626889)
- 2021-08-04 21:45 UTC [SEC Form 4] [SEC Form 4: Mann Brenda covered exercise/tax liability with 63 units of Common Stock, decreasing direct ownership by 0.41% to 15,321 units](https://www.quantisnow.com/insight/sec-form-4-mann-brenda-covered-exercisetax-liability-with-63-1626888)
- 2021-08-04 21:46 UTC [SEC Form 4] [SEC Form 4: MANZO MICHAEL P. covered exercise/tax liability with 65 units of Common Stock, decreasing direct ownership by 0.42% to 15,378 units](https://www.quantisnow.com/insight/sec-form-4-manzo-michael-p-covered-exercisetax-liability-with-1626887)
- 2021-08-04 21:46 UTC [SEC Form 4] [SEC Form 4: FROM STEPHEN covered exercise/tax liability with 261 units of Common Stock, decreasing direct ownership by 0.38% to 69,044 units](https://www.quantisnow.com/insight/sec-form-4-from-stephen-covered-exercisetax-liability-with-261-1626886)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EYEG
- Earnings history: https://www.quantisnow.com/earnings/EYEG
- Dividend history: https://www.quantisnow.com/dividends/EYEG
- Insider transactions: https://www.quantisnow.com/insiders/EYEG
- Options chain: https://www.quantisnow.com/options/EYEG
- SEC 8-K filings only: https://www.quantisnow.com/company/EYEG/8-k
- RSS and alerts for EYEG: https://www.quantisnow.com/docs/rss-feeds.md
